Table q1_q4_2019_prescription_drugs_wac

Table: q1_q4_2019_prescription_drugs_wac_increases , manufacturer_name like I*

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000160	Incyte Corporation	12/31/2019	50881001060	Jakafi (Ruxolitinib) 10mg tablet / 60 count bottle	10/01/2019	309.00	13504.00	06/12/2028	Single Source Drug	None	1	Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000160	Incyte Corporation	12/31/2019	50881001560	Jakafi (Ruxolitinib) 15mg tablet / 60 count bottle	10/01/2019	309.00	13504.00	06/12/2028	Single Source Drug	None	1	Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000160	Incyte Corporation	12/31/2019	50881002060	Jakafi (Ruxolitinib) 20mg tablet / 60 count bottle	10/01/2019	309.00	13504.00	06/12/2028	Single Source Drug	None	1	Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000160	Incyte Corporation	12/31/2019	50881002560	Jakafi (Ruxolitinib) 25mg tablet / 60 count bottle	10/01/2019	309.00	13504.00	06/12/2028	Single Source Drug	None	1	Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000160	Incyte Corporation	12/31/2019	50881000560	Jakafi (Ruxolitinib) 5mg tablet / 60 count bottle	10/01/2019	309.00	13504.00	06/12/2028	Single Source Drug	None	1	Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000040	Ingenus Pharmaceuticals, LLC	09/30/2019	50742051330	Nitro-Dur Patch 0.1mg/hr 30 ct	08/01/2019	129.20	520.73	None	Single Source Drug	372	None	Increased overhead, expenses, and distribution costs causing need for price increase	None	No changes made	None	08/31/2017	USPharma	2000000	None	The acquisition price provided was for the acquisition of the Nitro-Dur product line from USPharma and is not a SKU specific figure	262.77	138.30	2017	262.77	None	Patent expiration date: as this product is pre-patent, we do not have a patent expiration date to provide Year Introduced to Market: only the 0.3mg sold in 2017, the rest of the SKUs were first sold in 2018. However, we loaded all SKUs to the Gold Standard with 2017 effective dates. Therefore, we have listed 2017 as the introduction year
Rx0000040	Ingenus Pharmaceuticals, LLC	09/30/2019	50742051430	Nitro-Dur Patch 0.2mg/hr 30 ct	08/01/2019	139.01	560.26	None	Single Source Drug	960	None	Increased overhead, expenses, and distribution costs causing need for price increase	None	No changes made	None	08/31/2017	USPharma	2000000	None	The acquisition price provided was for the acquisition of the Nitro-Dur product line from USPharma and is not a SKU specific figure	282.72	140.40	2017	282.72	None	Patent expiration date: as this product is pre-patent, we do not have a patent expiration date to provide Year Introduced to Market: only the 0.3mg sold in 2017, the rest of the SKUs were first sold in 2018. However, we loaded all SKUs to the Gold Standard with 2017 effective dates. Therefore, we have listed 2017 as the introduction year
Rx0000040	Ingenus Pharmaceuticals, LLC	09/30/2019	50742051530	Nitro-Dur Patch 0.3mg/hr 30 ct	08/01/2019	155.83	628.04	None	Single Source Drug	6744	None	Increased overhead, expenses, and distribution costs causing need for price increase	None	No changes made	None	08/31/2017	USPharma	2000000	None	The acquisition price provided was for the acquisition of the Nitro-Dur product line from USPharma and is not a SKU specific figure	316.92	157.50	2017	316.92	None	Patent expiration date: as this product is pre-patent, we do not have a patent expiration date to provide Year Introduced to Market: only the 0.3mg sold in 2017, the rest of the SKUs were first sold in 2018. However, we loaded all SKUs to the Gold Standard with 2017 effective dates. Therefore, we have listed 2017 as the introduction year
Rx0000040	Ingenus Pharmaceuticals, LLC	09/30/2019	50742051630	Nitro-Dur Patch 0.4mg/hr 30 ct	08/01/2019	155.83	628.04	None	Single Source Drug	510	None	Increased overhead, expenses, and distribution costs causing need for price increase	None	No changes made	None	08/31/2017	USPharma	2000000	None	The acquisition price provided was for the acquisition of the Nitro-Dur product line from USPharma and is not a SKU specific figure	316.92	157.50	2017	316.92	None	Patent expiration date: as this product is pre-patent, we do not have a patent expiration date to provide Year Introduced to Market: only the 0.3mg sold in 2017, the rest of the SKUs were first sold in 2018. However, we loaded all SKUs to the Gold Standard with 2017 effective dates. Therefore, we have listed 2017 as the introduction year
Rx0000040	Ingenus Pharmaceuticals, LLC	09/30/2019	50742051730	Nitro-Dur Patch 0.6mg/hr 30 ct	08/01/2019	169.00	681.13	None	Single Source Drug	420	None	Increased overhead, expenses, and distribution costs causing need for price increase	None	No changes made	None	08/31/2017	USPharma	2000000	None	The acquisition price provided was for the acquisition of the Nitro-Dur product line from USPharma and is not a SKU specific figure	343.71	170.70	2017	343.71	None	Patent expiration date: as this product is pre-patent, we do not have a patent expiration date to provide Year Introduced to Market: only the 0.3mg sold in 2017, the rest of the SKUs were first sold in 2018. However, we loaded all SKUs to the Gold Standard with 2017 effective dates. Therefore, we have listed 2017 as the introduction year
Rx0000040	Ingenus Pharmaceuticals, LLC	09/30/2019	50742051830	Nitro-Dur Patch 0.8mg/hr 30 ct	08/01/2019	169.00	681.13	None	Single Source Drug	4056	None	Increased overhead, expenses, and distribution costs causing need for price increase	None	No changes made	None	08/31/2017	USPharma	2000000	None	The acquisition price provided was for the acquisition of the Nitro-Dur product line from USPharma and is not a SKU specific figure	343.71	170.70	2017	343.71	None	Patent expiration date: as this product is pre-patent, we do not have a patent expiration date to provide
Rx0000266	Intercept Pharmaceuticals, Inc.	09/30/2019	69516001030	OCALIVA (obeticholic acid), 10mg tablets, 30 count bottle	08/15/2019	322.77	6909.83	04/26/2036	Single Source Drug	None	1	Intercept’s pricing decisions take into careful consideration a variety of interdependent factors, including R&D investments, clinical/economic value, patient affordability, and current market dynamics.	None	This WAC increase was not necessitated by a change or improvement in the product. Intercept’s goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	The drug was developed by the manufacturer; therefore the acquisition related fields are blank. Per State requirements, the information reported is limited to that which is otherwise in the public domain or publicly available.
Rx0000266	Intercept Pharmaceuticals, Inc.	09/30/2019	69516000530	OCALIVA (obeticholic acid), 5mg tablets, 30 count bottle	08/15/2019	322.77	6909.83	04/26/2036	Single Source Drug	None	1	Intercept’s pricing decisions take into careful consideration a variety of interdependent factors, including R&D investments, clinical/economic value, patient affordability, and current market dynamics.	None	This WAC increase was not necessitated by a change or improvement in the product. Intercept’s goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	The drug was developed by the manufacturer; therefore the acquisition related fields are blank. Per State requirements, the information reported is limited to that which is otherwise in the public domain or publicly available.
Rx0000084	Ipsen Biopharmaceuticals, Inc.	03/31/2019	15054104005	Drug product name: Increlex. Drug product strength: 10 mg/ml. Drug product dosage form: vial. Drug product package size: 4ml.	01/01/2019	403.01	4464.00	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. The product was not acquired by Ipsen within the previous five years.
Rx0000084	Ipsen Biopharmaceuticals, Inc.	03/31/2019	15054004301	Drug product name: Onivyde. Drug product strength: 43 mg/10 ml (4.3 mg/ml). Drug product dosage form: vial. Drug product package size: 10ml.	01/01/2019	194.00	2152.00	06/12/2033	Single Source Drug	None	1	None	1	None	1	04/03/2017	Merrimack Pharmaceuticals	None	1	For purposes of 22 CCR § 96070(b)(12)(c) (requirement to report the purchase price of the relevant drug, if the drug was acquired by the manufacturer within the previous five years), Ipsen purchased the global oncology assets of Merrimack Pharmaceuticals in April 2017, including Onivyde. The purchase price of the drug product (as Ipsen understands that data element) is not in the public domain or otherwise publicly available. However, information regarding Ipsen’s purchase of the assets from Merrimack Pharmaceuticals is available on p. 97, Note 12.1.1 of section 3.2.5, of the Registration Document located at: https://www.ipsen.com/websites/Ipsen_Online/wp-content/uploads/2018/03/15164935/IPSEN_DDR_2017_VA_complet_clean-003.pdf	1652.40	None	2015	1620.00	None	The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. The information provided in response to 22 CCR § 96070(b)(11) contains price increases for the drug product when the NDC for the product was 69171-0398-01
Rx0000084	Ipsen Biopharmaceuticals, Inc.	03/31/2019	15054112003	Drug product name: Somatuline Depot. Drug product strength: 120 mg/0.5 ml. Drug product dosage form: syringe. Drug product package size: .50 ml.	01/01/2019	718.00	7967.00	03/08/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Ipsen has provided the WAC history for the relevant NDC going back to January 2, 2015. The NDC at issue did not exist before that date. The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. The product was not acquired by Ipsen within the previous five years.
Rx0000084	Ipsen Biopharmaceuticals, Inc.	03/31/2019	15054106003	Drug product name: Somatuline Depot. Drug product strength: 60 mg/0.2 ml. Drug product dosage form: syringe. Drug product package size: .20 ml.	01/01/2019	457.00	5072.00	03/08/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Ipsen has provided the WAC history for the relevant NDC going back to January 2, 2015. The NDC at issue did not exist before that date. The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. The product was not acquired by Ipsen within the previous five years.
Rx0000084	Ipsen Biopharmaceuticals, Inc.	03/31/2019	15054109003	Drug product name: Somatuline Depot. Drug product strength: 90 mg/0.3 ml. Drug product dosage form: syringe. Drug product package size: .30 ml.	01/01/2019	609.00	6756.00	03/08/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Ipsen has provided the WAC history for the relevant NDC going back to January 2, 2015. The NDC at issue did not exist before that date. The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. The product was not acquired by Ipsen within the previous five years.